Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company, has announced a webcast presentation of initial Phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC. The webcast is scheduled for Monday, September 23, 2024, at 8:00 a.m. ET.
Black Diamond specializes in developing MasterKey therapies targeting families of oncogenic mutations in cancer patients. The presentation will be accessible under the 'Events and Presentations' section of the company's website, with a replay available after the event.
Black Diamond Therapeutics (Nasdaq: BDTX), un'azienda oncologica in fase clinica, ha annunciato una presentazione in webcast dei risultati iniziali del trial clinico di Fase 2 per BDTX-1535 in pazienti con NSCLC EGFRm ricorrente. Il webcast è previsto per lunedì 23 settembre 2024, alle 8:00 ET.
Black Diamond si specializza nello sviluppo di terapie MasterKey che mirano a famiglie di mutazioni oncogeniche nei pazienti affetti da cancro. La presentazione sarà accessibile nella sezione 'Eventi e Presentazioni' del sito web dell'azienda, con una registrazione disponibile dopo l'evento.
Black Diamond Therapeutics (Nasdaq: BDTX), una empresa de oncología en fase clínica, ha anunciado una presentación por webcast de los resultados iniciales del ensayo clínico de Fase 2 para BDTX-1535 en pacientes con NSCLC EGFRm recurrente. La transmisión está programada para el lunes 23 de septiembre de 2024, a las 8:00 a.m. ET.
Black Diamond se especializa en desarrollar terapias MasterKey que abordan familias de mutaciones oncogénicas en pacientes con cáncer. La presentación estará disponible en la sección 'Eventos y Presentaciones' del sitio web de la compañía, con una repetición accesible después del evento.
블랙 다이아몬드 테라퓨틱스(Nasdaq: BDTX), 임상 단계의 종양학 회사는 재발성 EGFRm NSCLC 환자를 위한 BDTX-1535의 초기 2상 임상 시험 결과에 대한 웹캐스트 발표를 발표했습니다. 웹캐스트는 2024년 9월 23일 월요일, 오전 8시 ET로 예정되어 있습니다.
블랙 다이아몬드는 암 환자의 종양 유전자 돌연변이 가족을 겨냥한 마스터키 치료법을 개발하는 전문 회사입니다. 발표는 회사 웹사이트의 '이벤트 및 발표' 섹션에서 접근 가능하며, 이벤트 후 재방송이 제공될 예정입니다.
Black Diamond Therapeutics (Nasdaq: BDTX), une entreprise d'oncologie en phase clinique, a annoncé une présentation par webcast des résultats initiaux de l'essai clinique de Phase 2 pour BDTX-1535 chez des patients atteints de NSCLC EGFRm récurrent. Le webcast est prévu pour le lundi 23 septembre 2024 à 8h00 ET.
Black Diamond se spécialise dans le développement de thérapies MasterKey visant des familles de mutations oncogéniques chez les patients atteints de cancer. La présentation sera accessible dans la section 'Événements et Présentations' du site Web de l'entreprise, avec un replay disponible après l'événement.
Black Diamond Therapeutics (Nasdaq: BDTX), ein onkologisches Unternehmen in der klinischen Phase, hat eine Webcast-Präsentation der ersten Phase 2 klinischen Studienergebnisse für BDTX-1535 bei Patienten mit wiederkehrendem EGFRm NSCLC angekündigt. Der Webcast ist für Montag, den 23. September 2024 um 8:00 Uhr ET angesetzt.
Black Diamond spezialisiert sich auf die Entwicklung von MasterKey-Therapien, die Familien von onkogenen Mutationen bei Krebspatienten anvisieren. Die Präsentation wird im Bereich 'Veranstaltungen und Präsentationen' auf der Website des Unternehmens zugänglich sein, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- Reaching Phase 2 clinical trial stage for BDTX-1535
- Potential progress in treating recurrent EGFRm NSCLC
- None.
Webcast to be held Monday, September 23, at 8:00 a.m. ET
CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET.
Webcast information
The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
For Media:
media@bdtx.com
FAQ
What is the date and time of Black Diamond Therapeutics' webcast for BDTX-1535 Phase 2 data?
What type of cancer is BDTX-1535 being tested for in the Phase 2 trial?
Where can investors access Black Diamond Therapeutics' (BDTX) webcast presentation?
What is Black Diamond Therapeutics' (BDTX) focus in oncology treatment?
